articleTop 1% cited

Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases

Annals of Surgery · 2010 · Vol. 252(3) · pp. 426–433

Armando E. Giuliano✉(Saint John's Health Center)Linda McCall(American College of Surgeons)Peter D. Beitsch(Dallas Surgical Group)Pat W. Whitworth(Mayo Clinic in Arizona)Peter Blumencranz(Morton Plant Hospital)A. Marilyn Leitch(The University of Texas Southwestern Medical Center)Sukamal Saha✉(Saint John's Health Center)Kelly K. Hunt(American College of Surgeons)Monica Morrow(Memorial Sloan Kettering Cancer Center)Karla V. Ballman(Mayo Clinic in Arizona)

View via DOI Publisher page

Abstract

Despite the potential for residual axillary disease after SLND, SLND without ALND can offer excellent regional control and may be reasonable management for selected patients with early-stage breast cancer treated with breast-conserving therapy and adjuvant systemic therapy.

Head and Neck Cancer Studies Cancer Diagnosis and Treatment Breast Cancer Treatment StudiesMedicineSentinel lymph nodeAxillary Lymph Node DissectionDissection (medical)Axillary DissectionLymph nodeSentinel nodeRadiologyAxillaLymph

MeSH terms

AdultAgedAged, 80 and overAxillaBreast NeoplasmsFemaleHumansLymph Node ExcisionLymphatic MetastasisNeoplasm Recurrence, LocalPrognosisProspective StudiesSurvival RateChi-Square DistributionSentinel Lymph Node Biopsy

Citations

1,242

FWCI

78.52

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers